Related references
Note: Only part of the references are listed.Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study
Lucas Hendrik Overeem et al.
CEPHALALGIA (2022)
Alpha-Calcitonin Gene Related Peptide: New Therapeutic Strategies for the Treatment and Prevention of Cardiovascular Disease and Migraine
Ambrish Kumar et al.
FRONTIERS IN PHYSIOLOGY (2022)
Biological and small molecule strategies in migraine therapy with relation to the calcitonin gene-related peptide family of peptides
Lars Edvinsson et al.
BRITISH JOURNAL OF PHARMACOLOGY (2022)
Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data
David W. Dodick et al.
HEADACHE (2021)
Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis
Konstantina Drellia et al.
CEPHALALGIA (2021)
Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine
Fred Cohen et al.
PAIN MEDICINE (2021)
Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
Andrew M. Blumenfeld et al.
PAIN AND THERAPY (2021)
Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon
Ilana D. Breen et al.
JAMA NETWORK OPEN (2021)
Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study
Shuu-Jiun Wang et al.
CEPHALALGIA (2021)
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice
Jessica Ailani et al.
HEADACHE (2021)
The evolving understanding of risk with calcitonin gene-related peptide monoclonal antibodies based on real-world data: A focus on hypertension and Raynaud phenomenon
Ilana D. Breen et al.
HEADACHE (2021)
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study
Takao Takeshima et al.
HEADACHE (2021)
Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial
Paul K. Winner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
A Review of Eptinezumab Use in Migraine
Abhigyan Datta et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2021)
Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine
David W. Dodick et al.
CEPHALALGIA (2021)
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
Messoud Ashina et al.
CEPHALALGIA (2020)
Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting
Anne-Sophie Wattiez et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2020)
Expression of the CGRP Family of Neuropeptides and their Receptors in the Trigeminal Ganglion
Lars Edvinsson et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2020)
Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
Richard B. Lipton et al.
NEUROLOGY (2020)
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
Wim M. Mulleners et al.
LANCET NEUROLOGY (2020)
Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019
T. J. Steiner et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine
Brian Baker et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2020)
Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed
Pamela Vo et al.
CEPHALALGIA (2019)
A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody
William Kielbasa et al.
CEPHALALGIA (2019)
CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
Valentina Favoni et al.
JOURNAL OF HEADACHE AND PAIN (2019)
CGRP and the Trigeminal System in Migraine
Smriti Iyengar et al.
HEADACHE (2019)
Effects of monoclonal antagonist antibodies on calcitonin gene-related peptide receptor function and trafficking
Raffi Manoukian et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial
David W. Dodick et al.
CEPHALALGIA (2019)
Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review
Hsiangkuo Yuan et al.
HEADACHE (2019)
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
Michel D. Ferrari et al.
LANCET (2019)
Migraine and the trigeminovascular system-40 years and counting
Messoud Ashina et al.
LANCET NEUROLOGY (2019)
A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults
Fumihiko Sakai et al.
HEADACHE (2019)
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
Simona Sacco et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
Vladimir Skljarevski et al.
CEPHALALGIA (2018)
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
David W. Dodick et al.
CEPHALALGIA (2018)
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine A Randomized Clinical Trial
David W. Dodick et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Evaluation of Galcanezumab for the Prevention of Episodic Migraine The EVOLVE-1 Randomized Clinical Trial
Virginia L. Stauffer et al.
JAMA NEUROLOGY (2018)
Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents
Christina L. Szperka et al.
HEADACHE (2018)
Basic Considerations for the Use of Monoclonal Antibodies in Migraine
Morris Levin et al.
HEADACHE (2018)
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
Uwe Reuter et al.
LANCET (2018)
Galcanezumab in chronic migraine The randomized, double-blind, placebo-controlled REGAIN study
Holland C. Detke et al.
NEUROLOGY (2018)
Overview of Neuropeptides: Awakening the Senses?
Andrew F. Russo
HEADACHE (2017)
Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors
Agustin Melo-Carrillo et al.
JOURNAL OF NEUROSCIENCE (2017)
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Stewart Tepper et al.
LANCET NEUROLOGY (2017)
Fremanezumab for the Preventive Treatment of Chronic Migraine
Stephen D. Silberstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Controlled Trial of Erenumab for Episodic Migraine
Peter J. Goadsby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects
Thuy Vu et al.
PHARMACEUTICAL RESEARCH (2017)
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
Hong Sun et al.
LANCET NEUROLOGY (2016)
Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program
Marcelo E. Bigal et al.
CEPHALALGIA (2014)
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
David W. Dodick et al.
LANCET NEUROLOGY (2014)
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
David W. Dodick et al.
LANCET NEUROLOGY (2014)
CALCITONIN GENE-RELATED PEPTIDE: PHYSIOLOGY AND PATHOPHYSIOLOGY
F. A. Russell et al.
PHYSIOLOGICAL REVIEWS (2014)
CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat
J. Zeller et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Involvement of calcitonin gene-related peptide in control of human fetoplacental vascular tone
YL Dong et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2004)
Share Paper
